Scholars Central

Research articlePublished 30 Oct 2023

Therapeutic Methods and Pancreatic Cancer Stem Cells

Authors: Hari Prasad Sonwani

Department of Pharmacy, Apollo Group of Institution, Durg, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

With 1-5% 5-year survival rates (6-month median survival duration) despite medication, pancreatic ductal adenocarcinoma (PDAC), one of the deadliest human malignancies, provides an unmet therapeutic challenge. PDAC accounts for 90% of all pancreatic malignancies and is the most prevalent histological subtype. It is a very aggressive and complex malignancy that manifests with early local invasion and metastasis and is resistant to the majority of treatments, all of which are thought to be factors in its incredibly bad prognosis. PDAC is characterized by molecular changes, including as mutations of the WNT, K-RAS, TP53, Hedgehog, transforming growth factor-, and NOTCH signaling pathways (90% of cases). Given that cancer stem cells play a significant role in medication resistance, the relapse or recurrence of numerous diseases, as well as tumor start and progression. They might make good targets for potent, cutting-edge medicinal strategies. Here, we examined contemporary treatment approaches that use chemotherapeutics and targeted medicines, non-coding RNAs (siRNA and miRNAs), immunotherapy, and natural substances to target pancreatic cancer stem cells.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Inflammation, Cancer and Integrative Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Inflammation, Cancer and Integrative Therapy
  • SubjectImmunology & Microbiology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Hari Prasad Sonwani”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels